These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 21995398)
1. Vemurafenib in melanoma with BRAF V600E mutation. Morita H; Nagai R N Engl J Med; 2011 Oct; 365(15):1448; author reply 1450. PubMed ID: 21995398 [No Abstract] [Full Text] [Related]
2. Vemurafenib in melanoma with BRAF V600E mutation. Dalle S; Poulalhon N; Thomas L N Engl J Med; 2011 Oct; 365(15):1448-9; author reply 1450. PubMed ID: 21995399 [No Abstract] [Full Text] [Related]
3. Vemurafenib in melanoma with BRAF V600E mutation. Lott JP N Engl J Med; 2011 Oct; 365(15):1449-50; author reply 1450. PubMed ID: 21995400 [No Abstract] [Full Text] [Related]
4. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. Chapman PB; Hauschild A; Robert C; Haanen JB; Ascierto P; Larkin J; Dummer R; Garbe C; Testori A; Maio M; Hogg D; Lorigan P; Lebbe C; Jouary T; Schadendorf D; Ribas A; O'Day SJ; Sosman JA; Kirkwood JM; Eggermont AM; Dreno B; Nolop K; Li J; Nelson B; Hou J; Lee RJ; Flaherty KT; McArthur GA; N Engl J Med; 2011 Jun; 364(26):2507-16. PubMed ID: 21639808 [TBL] [Abstract][Full Text] [Related]
5. Vemurafenib: a guide to its use in unresectable or metastatic melanoma. Keating GM; Lyseng-Williamson KA Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082 [TBL] [Abstract][Full Text] [Related]
11. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Chapman PB; Robert C; Larkin J; Haanen JB; Ribas A; Hogg D; Hamid O; Ascierto PA; Testori A; Lorigan PC; Dummer R; Sosman JA; Flaherty KT; Chang I; Coleman S; Caro I; Hauschild A; McArthur GA Ann Oncol; 2017 Oct; 28(10):2581-2587. PubMed ID: 28961848 [TBL] [Abstract][Full Text] [Related]
12. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma. Owen JL; Lopez IE; Desai SR J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671 [TBL] [Abstract][Full Text] [Related]
13. Targeted inhibition of the BRAF pathway in a patient with stage IV melanoma. Buckley B; Pierce B JAAPA; 2018 May; 31(5):24-26. PubMed ID: 29698368 [TBL] [Abstract][Full Text] [Related]
14. FDA approves vemurafenib for treatment of metastatic melanoma. Oncology (Williston Park); 2011 Sep; 25(10):906. PubMed ID: 22010387 [No Abstract] [Full Text] [Related]
15. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505 [TBL] [Abstract][Full Text] [Related]
16. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714 [TBL] [Abstract][Full Text] [Related]
18. Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma. Luke JJ; Hodi FS Clin Cancer Res; 2012 Jan; 18(1):9-14. PubMed ID: 22083257 [TBL] [Abstract][Full Text] [Related]
19. Upcoming strategies for the treatment of metastatic melanoma. Spagnolo F; Queirolo P Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184 [TBL] [Abstract][Full Text] [Related]
20. A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib. Maleka A; Åström G; Byström P; Ullenhag GJ BMC Cancer; 2016 Aug; 16():634. PubMed ID: 27520988 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]